Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Janik Engelmann, Isabel Ben Batalla, PhD, Hanna Taipaleenmäki, PhD, Kristoffer Riecken, PhD, Victoria Gensch, Sarina Paesler, Nikolaus Berenbrok, Maria Elena Vargas, Jonas Waizenegger, MD, Boris Fehse, PhD, Klaus Pantel, MD, PhD, Ihab S Darwish, PhD, Somasekhar Bhamidipati, PhD, Esteban Masuda, PhD, Carsten Bokemeyer, MD, PhD, Eric Hesse, MD, PhD, Sonja Loges, MD, PhD

Blood (2018) 132 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2018-99-118273

Published: 2018

Journal Articles

Clones with and without Sensitivity Towards Treatment In Vivo Co-Exist within the Tumor Cells of a Single Patient with ALL

Cornelia Finkenzeller, MSc, Michela Carlet, PhD, Sebastian Vosberg, Christoph Ziegenhain, MSc, Martin Neumann, MD, Kristoffer Riecken, PhD, Kerstin Cornils, PhD, Boris Fehse, PhD, Claudia D. Baldus, MD, Wolfgang Enard, Prof. Dr. rer. nat., Philipp A. Greif, MD, Irmela Jeremias, MD

Blood (2016) 128 (22): 456.

https://doi.org/10.1182/blood.V128.22.456.456

Published: 2016

Journal Articles

Development of a Digital-PCR Assay for Screening and Quantitative Monitoring of Calreticulin (CALR) Type-2 Positive Patients with Myelofibrosis Following Allogeneic Stem Cell Transplantation

Boris Fehse, PhD, Anita Badbaran, Maximilian Christopeit, MD, Tim Aranyossy, Francis Ayuk, MD, Christine Wolschke, MD, Nicolaus Kroeger

Blood (2015) 126 (23): 1959.

https://doi.org/10.1182/blood.V126.23.1959.1959

Published: 2015

Journal Articles

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Blood (2015) 126 (23): 352.

https://doi.org/10.1182/blood.V126.23.352.352

Published: 2015

Journal Articles

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Nicolaus Kroeger, Anita Badbaran, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuk, MD, Axel R. Zander, Professor, Haefaa Alchalby, MD, Ulrike Bacher, Ioanna N Triviai, PhD, Boris Fehse, PhD

Blood (2015) 126 (23): 4343.

https://doi.org/10.1182/blood.V126.23.4343.4343

Published: 2015

Journal Articles

Chimerism Analyses in Stem Cell Recipients with Non Hodgkin Lymphoma

Gabriela Bernadeta Iwanski, MD, Sunday Ocheni, MD, Maite Hartwig, MD, Boris Fehse, PhD, Tatjana Zabelina, MD, Alexander Muth, MD, Silke Zeschke, Friederike Lehmann, Axel R. Zander, MD, Nicolaus Kroeger, Sr., MD, Ulrike Bacher, MD

Blood (2008) 112 (11): 4327.

https://doi.org/10.1182/blood.V112.11.4327.4327

Published: 2008

Journal Articles

NPM1 Mutations Are Valid Minimal Residual Disease Parameters Following Allogeneic Stem Cell Transplantation: A Study on 116 AML Patients.

Ulrike Bacher, MD, Anita Badbaran, Axel R. Zander, MD, Boris Fehse, PhD, Nicolaus Kroger, MD

Blood (2007) 110 (11): 1655.

https://doi.org/10.1182/blood.V110.11.1655.1655

Published: 2007

Journal Articles

High Efficiency Retro- and Lentiviral Transduction of Blood Endothelial Outgrowth Cells

Marcus A. Stockschlaeder, MD, Olga Shardakova, MD, Boris Fehse, PhD, Rudiger E. Scharf, MD

Blood (2007) 110 (11): 3727.

https://doi.org/10.1182/blood.V110.11.3727.3727

Published: 2007

Journal Articles

Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, ΔTrkA.

Zhixiong Li, MD, Johann Meyer, PhD, Mathias Rhein, Olga Kustikova, PhD, Cornelia Rudolph, PhD, Kenji Kamino, MD, Thomas Neumann, Min Yang, BSc, Anke Wahlers, PhD, Boris Fehse, PhD, Gary W. Reuther, PhD, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Christopher Baum, MD

Blood (2006) 108 (11): 1442.

https://doi.org/10.1182/blood.V108.11.1442.1442

Published: 2006

Journal Articles

Kinetics of Plasma-Cell Chimerism after Allogeneic Stem Cell Transplantation by Real-Time PCR and Its Value To Quantify Minimal Residual Disease in Patients with Multiple Myeloma.

Nicolaus Kroeger, MD, Maria Zagrivnaja, PhD, Sabine Schwartz, Anita Badbaran, Tatjana Zabelina, MD, Francis Ayuk, MD, Axel Zander, MD, Boris Fehse, PhD

Blood (2005) 106 (11): 2748.

https://doi.org/10.1182/blood.V106.11.2748.2748

Published: 2005

Journal Articles

Insertion Sites of Retroviral Gene-Marking Vectors Influence the Contribution of Individual, Non-Malignant Cell Clones to Long-Term Hematopoiesis.

Olga Kustikova, PhD, Zhixiong Li, MD, Christopher Baum, MD, Boris Fehse, PhD

Blood (2004) 104 (11): 293.

https://doi.org/10.1182/blood.V104.11.293.293

Published: 2004

Journal Articles

Aldehyde Dehydrogenase Activity - the Better Marker for the Quality of Hematopoietic Stem Cell Transplants?!.

Michael V. Lioznov, MD, Petra Freiberger, Axel R. Zander, MD, Boris Fehse, PhD

Blood (2004) 104 (11): 4997.

https://doi.org/10.1182/blood.V104.11.4997.4997

Published: 2004

Journal Articles

Collaborative RISC-Score Database: Creation of an International Database for Retroviral Integration Analysis.

Stephanie Laufs, Phd, Frank Giordano, Daniel Lauterborn, K. Zsuzsanna Nagy, Kurt Fellernberg, Phd, Agnes Hotz-Wagenblatt, Phd, Guillermo Guenechea, Phd, Boris Fehse, Phd, Juan B. Bueren, Phd, Axel Zander, MD, Cynthia E. Dunbar, MD, W. Jens Zeller, MD, Stefan Fruehauf, MD

Blood (2004) 104 (11): 2110.

https://doi.org/10.1182/blood.V104.11.2110.2110

Published: 2004

Journal Articles

Early In Vivo Depletion of Suicide Gene-Modified T-Lymphocytes Transplanted in Conjunction with CD34 + Enriched Blood Stem Cells May Be Associated with an Increased Risk of Secondary Graft Failure.

Boris Fehse, PhD, Francis A. Ayuk, MD, Nicolaus Kröger, MD, Lubin Fang, MD, Klaus Kühlcke, PhD, Marion Heinzelmann, Tatjana Zabelina, MD, Axel A. Fauser, MD, PhD, Axel R. Zander, MD

Blood (2004) 104 (11): 1742.

https://doi.org/10.1182/blood.V104.11.1742.1742

Published: 2004

Journal Articles

Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.

Nicolaus Kroeger, MD, Avichai Shimoni, MD, Maria Zagrivnaja, PhD, Francis Ayuk, MD, Michael Lioznov, PhD, Heike Schieder, MD, Boris Fehse, PhD, Tatjana Zabelina, MD, Arnon Nagler, MD, Axel Zander, MD

Blood (2004) 104 (11): 1646.

https://doi.org/10.1182/blood.V104.11.1646.1646

Published: 2004

NARROW

Blockade of Mer By the Small Molecule Inhibitor R992 Inhibits Multiple Myeloma and Its Associated Bone Disease By Restoring the Perturbed Bone Homeostasis

Clones with and without Sensitivity Towards Treatment In Vivo Co-Exist within the Tumor Cells of a Single Patient with ALL

Development of a Digital-PCR Assay for Screening and Quantitative Monitoring of Calreticulin (CALR) Type-2 Positive Patients with Myelofibrosis Following Allogeneic Stem Cell Transplantation

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Chimerism Analyses in Stem Cell Recipients with Non Hodgkin Lymphoma

NPM1 Mutations Are Valid Minimal Residual Disease Parameters Following Allogeneic Stem Cell Transplantation: A Study on 116 AML Patients.

High Efficiency Retro- and Lentiviral Transduction of Blood Endothelial Outgrowth Cells

Leukemogenic Cascade Induced by a Constitutively Active Neurotrophin Receptor, ΔTrkA.

Kinetics of Plasma-Cell Chimerism after Allogeneic Stem Cell Transplantation by Real-Time PCR and Its Value To Quantify Minimal Residual Disease in Patients with Multiple Myeloma.

Insertion Sites of Retroviral Gene-Marking Vectors Influence the Contribution of Individual, Non-Malignant Cell Clones to Long-Term Hematopoiesis.

Aldehyde Dehydrogenase Activity - the Better Marker for the Quality of Hematopoietic Stem Cell Transplants?!.

Collaborative RISC-Score Database: Creation of an International Database for Retroviral Integration Analysis.

Early In Vivo Depletion of Suicide Gene-Modified T-Lymphocytes Transplanted in Conjunction with CD34 + Enriched Blood Stem Cells May Be Associated with an Increased Risk of Secondary Graft Failure.

Low Dose Thalidomide and Donor Lymphocyte Infusion as Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only